Prospective Study for the Development, Validation and Confirmation of a Multi-Cancer Early Detection Platform Through Whole-Genome Sequencing Analysis of Circulating DNA in Cancer and Non-Cancer Subjects

Inclusion Criteria: 1. Adults aged 19 years or older 2. Individuals who understand the study and voluntarily provide informed consent. 3. (only for cancer participants) Participants with newly diagnosed solid tumors (Stage I-IV, including brain tumors) or hematologic malignancies who: * Have a histologically confirmed diagnosis (including bone marrow biopsy), or * Are highly suspected of having cancer based on clinical and/or radiologic evaluation and are scheduled for surgical resection after blood collection; and * Have not yet initiated any treatment (chemotherapy, targeted therapy, hormonal therapy, immunotherapy, radiotherapy, surgical resection, etc.). 4. (only for non-cancer participants) Individuals with no prior history of cancer. 5. (only for non-cancer participants) Individuals scheduled to undergo chest and/or abdominal CT or MRI imaging. Exclusion Criteria: 1. Pregnancy (self-reported pregnancy status). 2. Individuals for whom blood collection is deemed difficult by the investigator. 3. Individuals with a history of infection with HIV, HTLV, or syphilis. 4. (only for non-cancer participants) Individuals diagnosed with another malignancy within the past 5 years (exceptions: non-melanoma skin cancer, in-situ malignancies, thyroid cancer, and cervical intraepithelial neoplasia treated with curative intent). 5. (only for non-cancer participants) Individuals with cancer of unknown primary origin. 6. (only for non-cancer participants) Individuals with synchronous or metachronous multiple primary cancers.